# US 2015/0175688 A1 · Production cell line enhancers

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2015/0175688 A1
- Document ID: US20150175688A1
- Status: Published application
- Kind: A1
- Application number: 14/555,220
- Filed: 2014-11-26
- Published: 2015-06-25
- Earliest claimed: 2012-05-29
- Assignees: Regeneron Pharmaceuticals, Inc.
- Applicants: Regeneron Pharmaceuticals, Inc.
- Inventors: Gang CHEN; Darya BURAKOV; Dipali DESHPANDE
- Web page: https://patentgrep.com/patent/US20150175688A1

## CPC

- C07K 16/22: against growth factors {; against growth regulators}
- C07K 14/47: from mammals
- C07K 14/4705: {stimulating, promoting or activating activity}
- C07K 16/00: Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C12N 9/2488: {Mannanases}
- C12N 15/09: Recombinant DNA-technology
- C12N 15/79: Vectors or expression systems specially adapted for eukaryotic hosts
- C12N 15/85: for animal cells
- C12Y 302/01: Glycosidases, i.e. enzymes hydrolysing O- and S-glycosyl compounds (3.2.1)
- C07K 2317/14: Specific host cells or culture conditions, e.g. components, pH or temperature
- C07K 2317/51: Complete heavy chain or Fd fragment, i.e. VH + CH1
- C07K 2317/515: Complete light chain, i.e. VL + CL
- C12N 15/63: Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N 2015/8518: {expressing industrially exogenous proteins, e.g. for pharmaceutical use, human insulin, blood factors, immunoglobulins, pseudoparticles}
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)
- C12Y: ENZYMES

## Abstract

The present invention relates to discovery of the ectopic expression of EDEM2 in a production cell to improve the yield of a useful multi-subunit protein. Thus, the present invention provides for production cell lines, such as the canonical mammalian biopharmaceutical production cell—the CHO cell, containing recombinant polynucleotides encoding EDEM2. Also disclosed is a production cell containing both an EDEM2-encoding polynucleotide as well an XBP1-encoding polynucleotide. Improved titers of antibodies produced by these cell lines are disclosed, as well as the improved cell densities attained by these cells in culture.

## Claims

### Claim 1

An isolated polynucleotide comprising a nucleotide sequence, which encodes an EDEM2, a multi-subunit protein, and operably linked to a promoter, wherein the EDEM2 comprises an amino acid sequence that is at least 92% identical to SEQ ID NO:1.

### Claim 2 (depends on 1)

The isolated polynucleotide of claim 1, wherein the promoter is selected from the group consisting of ubiquitin C, CMV-IE and SV40.

### Claim 3 (depends on 2)

The isolated polynucleotide of claim 2, wherein the EDEM2 comprises the amino acid sequence of SEQ ID NO: 8.

### Claim 4 (depends on 2)

The isolated polynucleotide of claim 2, wherein the EDEM2 consists essentially of the amino acid sequence of SEQ ID NO: 8.

### Claim 5 (depends on 2)

The isolated polynucleotide of claim 2, wherein the EDEM2 comprises the amino acid sequence of SEQ ID NO: 1.

### Claim 6 (depends on 2)

The isolated polynucleotide of claim 2, wherein the EDEM2 consists essentially of the amino acid sequence of SEQ ID NO: 1.

### Claim 7 (depends on 5)

The polynucleotide of claim 5 comprising the nucleotide sequence of SEQ ID NO: 16.

### Claim 8 (depends on 5)

The polynucleotide of claim 5 comprising the nucleotide sequence of SEQ ID NO: 14 or SEQ ID NO: 15.

### Claim 9 (depends on 5)

The polynucleotide of claim 5 consisting essentially of the nucleotide sequence of SEQ ID NO: 14 or SEQ ID NO: 15.

### Claim 10

A cell-line comprising clonally-derived constituent cells comprising (1) an EDEM2-encoding polynucleotide, (2) an antibody heavy chain-encoding polynucleotide, and (3) an antibody light chain-encoding polynucleotide.

### Claim 11 (depends on 10)

The cell-line of claim 10, wherein the constituent cell is a CHO-K1 cell.

### Claim 12 (depends on 11)

The cell-line of claim 11, wherein the EDEM2-encoding polynucleotide comprises a nucleotide sequence of SEQ ID NO: 1.

### Claim 13 (depends on 10)

The cell-line of claim 10, wherein the EDEM2-encoding polynucleotide is operably linked to a promoter selected from the group consisting of ubiquitin C, CMV-IE and SV40.

### Claim 14 (depends on 10)

The cell-line of claim 10, wherein the cell-line is able to attain an integrated cell density that is at least about 50% greater, at least 60% greater, or at least 90% greater than the integrated cell density of a cell line that does not contain an EDEM2-encoding polynucleotide.

### Claim 15 (depends on 14)

The cell-line of claim 14, wherein the integrated cell density of the cell-line is assessed after about 12 days in culture.
